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 This review provides an update on histamine, on diamine oxidase (DAO) and on their implications in 
allergy and various conditions or affections, such as food histaminosis and inflammatory bowel diseases 
(IBD). The review also presents, in brief, patent coverage on therapies for allergy and IBD with the focus on 
histamine-related treatments. 
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Introduction 
 Amine oxidases (AOs), ubiquitarian enzymes widely distributed among living organisms [1],  catalyse 
the oxidation of monoamines and polyamines [2]. Histamine and other primary amines released during 





). AOs can be divided into two classes, depending whether if the prosthetic group is 
flavin adenine dinucleotide (FAD) or 2,4,5-trihydroxyphenylalanine quinone (TPQ), a cofactor derived from 
the post-translational oxidation of a tyrosine residue. This second group of enzymes (CuAOs, EC 1.4.3.6) 
contains copper and TPQ.  Among the Cu-TPQ class, plant CuAOs enzymes are, in general, more efficient 
than the animal ones, probably because they function through a radical mechanism which does not operate 
in animal CuAO enzymes [3].  
 Many physiological functions are ascribed to AOs. Although the exact molecular mechanism of the 
biological activity is not completely defined, a role of these enzymes in various diseases has been 
postulated. The patho-physiological relevance of histamine, polyamines, hydrogen peroxide and aldehydes 
in cell differentiation, cell death, allergic diseases and post-ischemic reperfusion damage was studied.  
Furthermore, a relationship between the plasmatic activity of benzylamine oxidase (Bz-AO) and diabetes has 
been described [2].  
 
Role of polyamines and diamine oxidases in cell proliferation and differentiation 
 High polyamine levels are typical  for actively proliferating cell populations, while the reaction 
products are involved in  opposite effects, impairing  cell growth and proliferation in vitro and in vivo [2]. In 
fact, when the polyamine level is decreased by difluoromethylornithine, an inhibitor of ornithine 
decarboxylase, cell proliferation stops, and starts again when the levels of polyamines increase, indicating 
that  the high level of polyamines is a causative event and not a result of cell growth [4]. Cell growth and 
proliferation are impaired, in vitro and in vivo, in the presence of oxidized polyamines [5], and the aldehydes 
produced by their oxidation are involved in the inhibition of nucleic acid and protein synthesis [6]. Pig kidney 
DAO, immobilized on  Concanavallin A-Sepharose, injected intraperitoneally in mice with Ehrlich ascite 
tumor, inhibits cell growth probably through the formation of toxic aldehydes and/or H2O2 produced during 
oxidation of polyamines; a similar effect was observed in cultured Chinese hamster ovary cells treated with 
bovine serum amine oxidase (BSAO) and spermine [7]. Both aldehydes and H2O2 contributed to the 
inhibition of proliferation, at different levels and times. The presence of catalase abolished cytotoxicity in the 
first 20 min, whereas aldehyde dehydrogenase (ADH) protected over a period from 30 to 60 min. When 
catalase and ADH were present in the reaction medium, cytotoxicity was completely abolished for a period of 
60 min, indicating that H2O2 is the reaction product contributing to the early stage of cytotoxicity, while 
aldehydes have a toxic effect with longer incubation times. High temperatures enhanced cytotoxicity induced 
with BSAO incubation, due to an increased reaction time. Based on this information, the involvement of 
biogenic amine oxidation products in the hyperthermic sensitivity of tumor  cells  can be postulated [8].   
 In summary, BSAO and, in general, AOs could be considerd key enzymes in cell growth and 
differentiation processes, and, therefore, in growth regulation and/or tumor development. DAO activity 
increases up to 1,000-fold in the serum of pregnant women indicating a possible protecting role against the 
release of polyamines from the feto-placental unit. During pregnancy, plasma semicarbazide-sensitive amine 
oxidase (SSAO)  is significantly  elevated, while  in premature births a decrease of placental AO  activity was 
found [9]. 
 A correlation between the grade of tumor malignancy and AO activity was evidentiated in certain 
tumors, such as astrocytomas. However, in some patients with metastatic tumors, the activity of circulating 
DAO remained unchanged. Data are also available on LoVo wild type (LoVo WT) and drug resistant (LoVo 
DX) colon carcinoma cells, where polyamines were elevated. The results showed that H2O2, produced by 
spermidine oxidation induced by AO, was the most important factor responsible for cytotoxic effects on both 
cell lines. Drug resistant cell line was more sensitive to H2O2 and aldehydes, and this effect was not 
prevented by glutathione and other protective agents. The different enzyme  patterns, involved in the cell 
defence against H2O2 and  reactive oxygen species (ROS), should explain the different sensitivity to H2O2; 
moreover, in the tumor cells without catalase, the sensitivity to H2O2 is related to the cellular levels of 
glutathione peroxidase, glucose-6-phosphate dehydrogenase, gluthione peroxidase and reductase [10]. A 
direct relationship between DAO activity and tumor progression was shown by Kusche et al. [11] with 
azoxymethane treatment combined with the inhibition of DAO with aminoguanidine. After 52 weeks, none of 
the animals treated with azoxymethane was found to bear a tumor, while in the group treated with DAO 
inhibitor, tumors were detectable after 24 weeks. These evidences clearly indicate that AOs should be 
considered regulatory enzymes between biosynthetic and catabolic reactions. 
 
Antiallergic and anti-anaphylactic effects of diamine oxidases 
 Histamine plays a fundamental role in anaphylaxis, and is involved in allergic and pseudoallergic 
reactions. Differently from other metabolic pathways, histaminase activity is not directly up-regulated by 
endogenously released histamine. Plasma histaminase activity increases in anaphylactic shock, but not 
during histamine injection [12]. In some cases, histaminase plasma levels are intrinsically low, predisposing 
to anaphylactic reactions. Enhanced histamine levels in humans could be related to various endogenous 
and/or exogenous factors. Food-induced histaminosis has been described as the result of high histamine 
content or histamine releasers present in food [13, 14]. The first symptom of excessive histamine intake 
and/or release is an increase in gastric secretion followed  by tachycardia, headache and hypotension [15, 
16].  A large amount of histamine is found in fermented foods, such as cheese, red wine, tinned tuna fish, 
fish sauces, sauerkraut, cured pork and sausages, oriental food and french cheeses, where concentrations 
higher than 800 µg/g can be found. Chemical de novo formation of amines may also occur during normal 
cooking and food storage [17]. The concept of pseudoallergic reactions to food, or false food allergies, was 
first suggested by Dukor et al. (1980), where the abnormal intake of biogenic amines, like histamine and 
tyramine, is one of the major mechanism involved [18]. The main clinical symptoms are represented by a 
drop of blood pressure, angioedema, headaches, alterations of intestinal functions skin, and respiratory 
symtoms.  High levels of histamine may also derive from the bacterial flora of the colon, especially in 
subjects with colonic dysmicrobism due to excessive intake of foods rich in cellulose and starch. Beside the 
excess of histamine, other histamine-dependent mechanisms of pseudoallergic reactions to food may 
include changes in the activity of the enzymes involved in the metabolism of histamine. A drop in 
histaminase and monoamine oxidase B (MAO B) levels was found in patients with atopic dermatitis [19]. 
Histaminase may also be inhibited by food toxins, sodium nitrite, antibiotics (clavulanic acid), and viral 
hepatitis [20]. Reduced DAO activity and histamine catabolism seem to be involved in episodes of 
bronchoconstriction occurring after intake of red wine or histamine-rich food, and  intestinal DAO is thought 
to be required for clearance of biogenic amines [21]. Elevated mucosal histamine content and secretion were 
observed in the gut of patients with allergic enteropathy, as well as in patients with Crohn’s disease and 
ulcerative colitis. In particular, there is evidence  that mast cell-derived inflammatory mediators, including 
histamine, play a major pathogenic role in these diseases [22]. 
The above findings indicate a possible therapeutic use of plant-derived histaminase, characterised 
by highly specific activity and ability to degrade various biogenic amines, including histamine and 
polyamines, in the treatment of allergic and pseudo-allergic diseases. 
 
Plant-derived diamine oxidase 
 Plant diamine oxidase (also known as histaminase, EC 1.4.3.6) is physiologically involved in 
oxidative deamination of various biogenic amines. Vegetal DAO is the most abundant soluble protein 
detected in the extracellular fluids of Fabaceae, in particular, in pea (Pisum sativum), lentil (Lens culinaris), 
and chickpea (Cicer arietinum) seedlings [23]. The plant histaminase differs from the mammalian and 
procaryotic enzymes in a number of peculiar features, mainly high turnover rate of catalysis, high binding 
affinity for histamine and high chemical stability. Moreover, this enzyme can be isolated to a high degree of 
purity with two simple and inexpensive chromatographic steps. An international Patent (n. PCT/EP01/13770) 
has been taken for a drug based on plant-derived histaminase for the treatment of histamine-mediated 
diseases, such as cardiac anaphylaxis, allergic asthma, allergic and septic shock, urticaria, rhinitis and 
conjunctivitis [24]. The main sources of histaminase are etiolated seedlings of leguminous plants, such as 
Pisum sativum, Lens culinaris, Cicer arietinum, and Latirus sativus, where this enzyme is present in high 
concentrations, up to 4% of total protein content. 
 
 Plant DAO/histaminase modulates allergic and anaphylactic responses 
 The massive release of histamine from tissue mast cells, elicited by the cross-linking of antigen with 
IgE bound to FCε receptors at the cell surface, is considered the paramount event in type I allergic  
reactions. The most commonly used experimental animal models for a type I allergic reaction encompasses 
cardiac anaphylaxis ex vivo and asthma-like reactions in sensitised guinea pigs in vivo. Pig kidney DAO has 
been shown to have antihistaminic activity in vivo and a protective role in guinea pig anaphylactic shock [25]. 
The protective effect of purified pea seedling histaminase, both free and immobilised on CNBr-Sepharose, in 
active cardiac anaphylaxis has been observed [25]. Briefly, guinea pigs were actively sensitised and 2-3 
weeks later, the heart was removed and perfused in a Langendorff apparatus, which allows an accurate 
determination of heart rate, contraction strength and coronary flow. Administration of antigen to the isolated 
hearts induced typical histamine-related changes in cardiac function. These changes consisted in a transient 
increase followed by a long-lasting reduction of myocardial contractility, an increase in heart rate and 
occurrence of severe arrhythmias and, a marked reduction in coronary flow. When antigen-challenge was 
performed in the presence of free or immobilised histaminase, the positive inotropic and chronotropic 
responses were fully blocked, including a dramatic decrease in the occurrence of ventricular arrhythmias and 
of the levels of histamine in the perfusates. As expected, histaminase preparations did not reduce mast cell 
degranulation in response to the allergen, presenting any chromoglycate-like effect on anaphylactic 
degranulation of mast cells, clearly demonstrating that the cardioprotective effect of free or immobilized 
histaminase was chiefly dependent on the inactivation of the released histamine [25]. Moreover, antigen-
challenge caused a slight decrease in cardiac cGMP and an increase in tissue Ca2+ levels, both effects 
being prevented by histaminase treatment. The mechanisms underlying these protective effects remain a 
matter of speculation, but we can correctly hypothesize that this effect could be mediated by an interaction 
with the nitric oxide (NO) synthase (NOS) pathway, since histaminase significantly increases cardiac NOS 
activity [25] and NO stimulates cardiac cGMP levels and decreases tissue Ca2+ concentrations [26]. 
 Allergic asthma is a major respiratory disease with a markedly increasing morbility worldwide. 
Despite decades of research, the pathogenic mechanisms are not completely understood; nevertheless, 
there is general agreement that histamine is a crucial mediator of the inflammation cascade and 
bronchospasm, two key features of allergic asthma. In this context, an experimental study to evaluate the 
effects of histaminase, free or immobilised, on asthma-like  reactions induced in antigen-sensitised guinea 
pigs by aerosolic exposure to the allergen has been published [27]. This animal model is known to reproduce 
respiratory abnormalities, airway hyperresponsiveness and leucocyte lung infiltration resembling to the 
functional and histopathological hallmarks of human allergic asthma [27, 28]. 
 Histaminase, free or immobilised on BrCN-Sepharose, was injected intraperitonneally (i.p.). The 
pharmacokinetic profiles showed higher amounts of histaminase in lungs from animals treated with the 
immobilised enzyme than in those treated with the free enzyme, and lower blood levels. The unexpected 
higher amounts of immobilised histaminase rather than free histaminase in the lungs could be ascribed to 
the fact that homing of the enzyme conjugate in those organs could be facilitated by the presence of 
galactose units in the molecule of the Sepharose vehicle. Challenge of ovalbumin-sensitised guinea pigs 
with aerosolised antigen resulted in severe abnormalities in their respiratory pattern, consisting of reduced 
latency time for the appearance of cough, increased cough severity and increased occurrence of dyspnaea 
and gasping, indicating the onset of respiratory failure. Pretreatment of animals with histaminase, i.p. or as 
aerosol solution, resulted in a marked reduction of breathing abnormalities and prevention of respiratory 
failure. Histaminase treatment also prevented the histopathological lung changes induced by antigen-
induced bronchospasm and reduced the inflammatory process characterized by leucocyte infiltration and 
oxygen free radical generation. In fact, histaminase decreases myeloperoxidase activity, a marker of tissue 
leucocyte infiltration, and malonyldialdehyde production, a marker of peroxidation of cell membrane lipids by 
ROS [27]. No relevant differences in pharmacological potency were noted between free and immobilized 
enzyme. 
 
Plant DAO/histaminase has a protective effect against ischemia-reperfusion injury 
 Besides its pivotal involvement in anaphylaxis and allergic reactions, histamine plays a role in 
exacerbation of inflammatory tissue damage, like many pro-inflammatory mediators, such as prostanoids 
and cytokines that are potent mast cell activators. In particular, histamine has been found to contribute to 
endothelial dysfunction, hampering of blood-tissue exchange and functional tissue impairment occurring in 
organs undergoing ischemia and reperfusion. On these grounds, we hypothesized that pea seedling 
histaminase could effectively prevent the adverse effects of cardiac and intestinal ischemia-reperfusion. In 
fact, the heart is particularly susceptible to tissue damage by several key agents involved in the 
pathophysiological mechanisms of ischemia-reperfusion, such as ROS, histamine and NO [29, 30]. During 
acute myocardial ischemia, the coronary sinus histamine concentration increases simultaneosly with the 
development of early arrhytmias [31]. Histamine released from cardiac mast cells can react with the medium, 
provoking coronary spasm and contributing to myocardial infarction [31, 32]. Moreover, an increase of 
plasma levels of AOs in congestive heart failure was found [33]. A close relationship between histamine, 
acting as a pro-oxidant, and ROS was observed in patients with coronary heart disease [30]. In turn, 
histamine release by mast cells is amplified by excessive superoxide generation and concurrent decrease in 
local amounts of NO, due to the fact that superoxide and NO react promptly, giving rise to harmful 
peroxinitrite [29]. Moreover, histamine per se induces a spasm of the coronary vessels, thereby causing or 
worsening acute coronary perfusion and myocardial ischemia. Histamine levels in the coronary sinus were 
increased by the occurrence and severity of ventricular arrhythmias. Pea seedling histaminase demonstrated 
cardioprotective effects against post-ischemic reperfusion damage, in the in vivo model of ischemia-
reperfusion in the rat. Briefly, anaesthesisedand artificially ventilated rats were subjected to 30 min of 
ischemia by the temporary occlusion of the left anterior descending coronary artery, followed then by 60 min 
of reperfusion.DAO., given intravenously either 10 min before reperfusion or exactly at reperfusion time 
(dose of 80 IU/kg b.w.), did not modify the at-risk area whereas the necrotic area was significantly reduced,  
and no cardiac protection was afforded by the semicarbazide-inactivated histaminase [34]. The number of 
animals which survived the 60 min-reperfusion was higher in the histaminase-treated groups than in the 
untreated one,  the analysis of ECG recordings  showing that histaminase reduced the occurrence of 
ventricular arrhythmias. DAO also reduced the biochemical tissue alterations induced by ischemia-
reperfusion.  Particularly, lung leucocyte infiltration, myocardial calcium overload and caspase-3 activation, a 
trigger enzyme for the activation of apoptotic cascade, were significantly reduced [34]. On these grounds, we 
hypothetized that pea seedling DAO could also effectively protect against the adverse effects of ischemia 
reperfusion of other organs, such as gut. To further validate our hypothesis, experiments on a rat model of 
splanchnic artery occlusion and reperfusion (SAO/R) were carried out. 
 Intestinal ischemia may result from impaired blood supply to the bowel by different causes, including 
cardiac insufficiency, sepsis, vaso- and cardio-depressant drugs and complications of long-lasting surgery 
[35]. Consequences of intestinal ischemia range from persistent bleeding and symptomatic intestinal 
strictures to bowel perforation and peritonitis. Surgical resection of the affected bowel segment is usually 
required to minimize adverse outcomes. The pathophysiology of intestinal ischemia has been widely 
investigated in laboratory, animals undergoing surgical occlusion of the splanchnic circulation being followed 
by reperfusion. This results in intestinal injury and circulatory shock, characterized by severe hypotension 
and hemoconcentration, associated with a high mortality rate [36]. It has been shown that the endothelial 
dysfunction plays a key role in intestinal ischemia, as it predisposes to vasospasm, platelet activation and 
increased neutrophil adherence, which exacerbates the local bowel injury as well as the general 
cardiocirculatory failure [37]. Endothelial-leukocyte interaction is known to involve specific surface 
glycoproteins known as endothelial cell adhesion molecules (ECAMs). The ECAMs include early-phase 
molecules, such as P-selectin, involved in leukocyte tethering and rolling, which is rapidly translocated from 
the Weibel-Palade bodies to the endothelial cell surface upon stimulation by histamine, hypoxia and ROS 
[38, 39], as well as late-phase molecules, such as E-selectin, vascular cell adhesion molecule (VCAM)-1 and 
intercellular adhesion molecule (ICAM)-1, involved in leukocyte adhesion and extravasation into the tissue, 
whose expression is induced by most inflammatory mediators, including histamine and cytokines [40, 41]. At 
reperfusion, neutrophil accumulation and activation in the ischemic bowel results in the local generation and 
release of free radicals, lysosomal hydrolases and chemotactic factors such as leukotrienes [42], which give 
a major contribution to tissue injury by causing further endothelial damage and leukocyte recruitment [43, 
44], plasma membrane peroxidation and DNA damage [45]. The activation of DNA repair enzyme poly-ADP-
ribose (PAR) synthetase can exacerbate intestinal mucosal injury and dysfunction [46]. Free radical-
mediated bowel tissue injury is largely attributable to peroxinitrite, the reaction product of superoxide anion 
and NO, a potent cytotoxic and pro-inflammatory molecule [29]. Moreover, a synergism between ROS and 
histamine acting as pro-oxidant was also observed in ischemic diseases [31]. The release of histamine from 
mast cells in the extracellular compartment and in blood is increased by excess superoxide anion and 
concurrent decrease of NO [47] and contributes to lethal circulatory shock occurring upon SAO/R. Histamine 
is released by the intestinal mucosa mostly during reperfusion [48] and  generates a vicious cycle that leads 
to further endothelial activation and leukocyte adhesion and extravasation. Moreover, along with the release 
of histamine, the activity of DAO is significantly reduced after 60 min ischemia [49]. In keeping with these 
findings, mast cell-deficient  mice (W/Wv) have been shown to be refractory to SAO/R-induced mucosal 
dysfunction [50]. In  an anesthetised rat model of 45 min splanchnic ischemia followed by 6 hours 
reperfusion, free histaminase (80 IU/kg b.w) given 15 min before reperfusion, significantly reduced the  drop 
in blood pressure and high mortality rate caused by SAO/R. Histaminase also reduced histopathological 
changes, leukocyte infiltration and expression of endothelial cell adhesion molecules in the ileum [51]. 
Beside reducing local tissue inflammation through acceleration of histamine catabolism, histaminase seemed 
to counteract ROS-mediated tissue injury, as indicated by the significant decrease in the tissue levels of 
peroxidation and nitration products, such as oxidized rhodamine, malonyldialdehyde and nitrotyrosine, of 
DNA damage markes, such as 8-hydroxy-2'-deoxyguanosine and poly-ADP-ribosylated DNA, and by 
consumption of tissue antioxidant enzymes, such as superoxide dismutase. As a result, histaminase lead to 
a reduction of ileal cell apoptosis, as assessed by the determination of caspase 3 activity, and of the number 
of  TUNEL-positive cells [51, 52].  As in the findings from cardiac ischemia-reperfusion, histaminase can 
afford protection against SAO/R-induced splachnic injury, probably due to oxidative catabolism of pro-
inflammatory histamine as well as due to its antioxidant effects [51]. This results in hindrance of free-radical-
mediated tissue injury, endothelial dysfuction and leukocyte recruitment. A schematic presentation of the 
mechanisms involved in the pathogenesis of SAO/R and on the protective effects of histaminase is shown in 
Fig. (1). A further explanation  regarding the mechanism of protection by DAO could be the effect of this 
class of enzymes on the modulation of K+ channels in the cells [53]; in fact a K+- channel opener protects 
cardiac mitochondria by decreasing oxidant stress at  reperfusion [54]. 
 
Role of amine oxidase in diabetes 
 The significance of increased plasma levels of benzylamine oxidases (BzAOs) in patients with 
diabetes is far from being clear. In diabetes, increased plasma BzAO is correlated with glycated 
haemoglobin [55], and the authors proposed it as an  independent marker for heart failure mortality [56]. 
These observations suggested a relationship between plasma BzAO enzyme activity, severity of diabetes 
and its cardiovascular complications. Insulin-sensitizing drugs reduced plasma BzAO, and this effect is part 
of the beneficial effect of these drugs. However, it is not known if plasma AO levels increase following 
diabetogenic drug therapies. The available information is the prominent favourable role of BzAO inhibitors in 
reducing the severity of diabetes-related cardiovascular complications [57].  
The activity of membrane-bound AOs spreads toxic aldehydes in the microenviroment that may 
initiate a deleteriuos cycle involving protein and DNA cross linkage related to angiotoxicity [58], a typical 
consequence of hyperglycemia and diabetes complications. Aminoguanidine, an inhibitor of BzAO and of 
NOS, has been added to common antidiabetic treatments, as a strategy to decrease the amount of glycated 
haemoglobin and the extent of protein-aging associated with the disease [59, 60]. In particular, in adipocytes 
and vascular smooth muscle cells, AO substrates generate a favourable microenvironment to remove local 
insulin resistance, but remain inactive with regard to the control of plasma glycemia. Pharmacological 
treatment of insulin resistance represents a first line approach to reduce diabetes-related complications. In 
recent years, many efforts focused on developing new drugs with fewer side effects, such as vanadium 
compounds, which lowered glycemia and normalized plasma lipid levels in an animal model of diabetes [61]. 
A novel combination of AO substrate and vanadium in low concentration has been proposed to increase the 
formation of peroxivanadate, an insulin-mimetic compound [62]. 
In conclusion, the control of therapeutic potential of AOs represents a field of growing interest in 
pharmacological research. The therapeutic potential of plant-derived histaminase in allergic diseases and 
anaphylactic shock and its ability to inhibit activation of a ROS-mediated inflammatory cascade and tissue 
injury has been investigated [51]. 
 
Recent Patent Application 
 Recently, an International Patent Application [24] proposing a histaminase-based drug of vegetable 
origin for the treatment of  histamine-mediated conditions has been described.  Compared to DAOs of 
mammalian origin, plant DAOs display: (i) high turnover rates of catalysis and high rates of reduced enzyme 
re-oxidation, (ii) high binding affinity for histamine (iii) and high stability. A plant DAO is currently on sale at 
MoLiRom srl, Rome, Italy. However, plant proteins, due to their phylogenetic distance from mammalian 
sources, generally exhibit a great difference in their primary sequence and consequently high 
immunogenicity. In order to overcome this problem and to increase the in vivo residence time, grass pea 
DAO has been modified using four activated PEGs with different molecular weights and shapes: 5 kDa 
PEG– Nle–OSu, 10 kDa PEG–pNO2 and 20 kDa PEG2–OSu. The modification reaction was carried out 
using various polymer/protein molar ratios. Gel filtration analysis of the reaction mixture revealed that a 
conjugate devoid of unmodified protein was obtained at 350:1 polymer/protein molar ratio. Under these 
conditions, about half of the amino groups were modified. This degree of modification could not be increased 
irrespective of the PEG molecular weight or the value of PEG/protein ratio, suggesting a limited availability of 
the amino groups at protein surface. This hindered PEGylation may be ascribed to the presence of sugars 
on the protein surface and/or to the dimeric structure of DAO that prevents, for steric reasons, the access of 
the polymer to all of the protein amino residues. PEGylation did not decrease the DAO activity, but, on the 
contrary, a significant increase (P ≤ 0.05), even if slight, was observed at high PEG conjugation values.  
 The immunological properties of either native or modified DAO, the ability to elicit anti–DAO IgG and 
IgM immunoresponse after mouse boosting with native DAO, PEG 5-DAO, PEG 10–DAO and PEG2 20-
DAO  were evaluated. This comparative study was carried out with the conjugates obtained by extensive 
modification with similar amino group derivatisation. These derivatives were expected to present the best 
immunological properties since the high polymer mass on the protein surface could mask efficiently the 
protein structure. IgG and IgM were selected as immunogenic biomarkers directly correlated to the protein 
immunogenicity. Native DAO is a highly immunogenic as its administration elicited high anti DAO IgM and 
IgG immuno-response following the second immunization. The 5 kDa and 10 kDa PEG derivatives elicited a 
slower immunoresponse and the maximal IgM concentration reached after the 5th immunization was about 
50% and 80% lower, respectively, compared to the native protein. The best result was obtained with PEG2 
20-DAO, eliciting only a negligible immunoresponse. The anti-DAO IgG profiles confirm the high 
immunogenic properties of this protein. The native protein induced maximal anti-DAO IgG concentration after 
3 immunizations. PEG 5-DAO and PEG 10-DAO induced a slower immunoresponse, and the antibody 
generation was about 95% lower than that obtained with the native protein. Also in this case the 
immunogenic character of PEG2 20-DAO was negligible.  
The pharmacokinetic behaviour of native and of the most promising PEGylated DAO was evaluated 
by determining the time of enzymatic activity in serum after a single intravenous administration to mice. 
Interestingly, PEG2 20-DAO exhibits a significant increase in circulating life with respect to the native 
enzyme, as the half-life was about 10 min for the native enzyme and 3 hours for the conjugate. In both 
cases, the experimental data were found to fit a biexponential behaviour indicating that either the native or 
the modified enzyme undergoes a distribution into a peripheral compartment. The pharmacokinetic 
parameters calculated by the elaboration of the experimental data highlighted the differences between the 
two enzyme forms. The values of α and β phase half-lives (t1/2α and t1/2β, respectively) showed that 
PEGylation induces a dramatic prolongation of both distribution and elimination phases. The prolonged 
permanence of the PEGylated DAO in the blood stream was also demonstrated by the reduced clearance 
(Cl), which, in the case of the PEG2 20- DAO, was about ten times smaller compared to the native protein.  
We can conclude that,  due to the properties of this enzyme, in particular after conjugation with high mass 
PEG, new treatments for histamine-related disorders can be envisaged [63, 64]. Moreover, P. sativum 
copper amine oxidase has been used as a new biocatalytic route for the synthesis of N-amidino-2-
hydroxypyrrolidine. For the fist time, N-amidino-2-hydroxypyrrolidine, the product of agmatine oxidation by P. 
sativum copper amine oxidase, has been identified and characterized from structural and biochemical 
viewpoints. Notably, the enzymatic oxidation of agmatine leads to the cyclic compound N-amidino-2-
hydroxypyrrolidine, as the only detectable reaction product. In fact, the formation of 4-
guanidinobutyraldehyde was never observed. N-amidino-2-hydroxypyrrolidine inhibits competitively NOS-I, 
NOS-II and trypsin. This compound binds to the Glu597 and Glu371 carboxylate, present in NOS-I and NOS-
II, respectively (Glu296 in human NOS-II, which is required for substrate (i.e. L-arginine) recognition. 
Moreover, N-amidino-2-hydroxypyrrolidine binds to the trypsin specificity subsite S1 forming a salt bridge 
with the Asp189 carboxylate. The latter is required for position recognition of substrates and inhibitors of 
trypsin-like serine of the cationic amino acid residue present at the P1 proteinases. N-amidino-2-
hydroxypyrrolidine and agmatine displace efficiently [3H] clonidine from I1-R present in heart rat membranes. 
Interestingly, different physiological roles (i.e. neuronal neurotransmission and hypotensive protection of 
cardiovascular system) have been linked to agmatine, which has been reported to be the endogenous ligand 
for I-R1 and to represent the N-amidino-2 hydroxypyrrolidine precursor. In this respect, pleiotropic functional 
role(s) of N-amidino-2 hydroxypyrrolidine may be envisaged, as reported for agmatine.  Agmatine oxidation 
by P. sativum copper amine oxidase may therefore represent a new biocatalytic route for the synthesis of N-
amidino-2-hydroxypyrrolidine, possibly representing a lead compound for the development of NOS and 
trypsin-like serine protease inhibitors. Moreover, N-amidino-2-hydroxypyrrolidine may represent a new ligand 
for I1-R [65, 66].  
 Recently, a plant copper amine oxidase has been used to develop a novel and visual test for oral 
malodour [67]. Until now, the application of biogenic amines as bio-markers of oral malodour has been 
limited because of the complexity of their detection. This study explores the usability of a simple colorimetric 
reaction detecting amines in saliva as an adjunct test for the diagnosis of oral malodour. The colour reaction 
caused by a newly discovered enzyme capable of detecting amines in saliva was characterized in vitro. Two 
colour scales were developed by transforming the colours of selected dilutions of a mixture of cadaverine 
and putrescine into a 5- and a 10-point pink-colour scale. Afterwards, this new enzymatic test was used to 
assess the amount of amines in saliva samples of 50 volunteers with different degrees of oral malodour. The 
enzymatic reaction was shown to be linear towards the concentration of amines and stable over a time of 4 
h. Colour scores correlated well with organoleptic scores and also with methyl mercaptan and total sulfur 
compounds (total VSC). 
 The presented new test offers two main advantages: the possibility of confirming the presence or 
absence of bad breath without the necessity of having an extra device that requires maintenance and 
calibration, and an alternative to overcome the embarrassment that patients may experience with an 
organoleptic evaluation. Moreover, its simplicity makes it suitable for any type of consultation without 
requiring the training and calibration of an odour judge. In summary, the new test is able to detect amines 
efficiently in saliva. The results of the enzymatic reaction can be interpreted by using a simple colour scale. 
The level of detected amines clearly differs in patients with and without oral malodour. The performance of 
the test appears to be betterthan other salivary colour tests and similar to OralChromaTM, one of the most 
used adjunct tools in the diagnosis of oral malodour. 
 Based on these results, it has been concluded that regardless of the inability of amines to contribute 
directly to the odour of saliva, they can be used as an indicator for bad breath. The new test can be 
considered as a simple, sensitive and objective adjunct tool for the clinical diagnosis of oral malodour [67].  
 Finally, a DAO from Lathyrus sativus has been used as a biocatalytic component of an 
electrochemical biosensor for the determination of the biogenic amine index in wine and beer samples. DAO 
from L. sativus was amperometrically characterized, and the obtained results allowed to compare the 
enzyme to other amine oxidases and to evaluate its selectivity towards different typical biogenic amines.  
The DAO was immobilized and employed to develop a novel DAO-based amperometric biosensor; the latter 
was analytically characterized, using putrescine as standard, under flow injection conditions. In order to 
reduce the influence of a matrix effect, which could affect the detection of biogenic amines in real samples, a 
special SPE, employing two working electrodes, was used as transducer. This dual-working electrode SPE, 
coupled to the proper multimeter (µStat 400 bipotentiostat, Dropsens, Oviedo, Spain) and driven by the 
DropView™ Software,  allowed the simultaneous registration of both sample and blank signals and 
eventually to subtract the latter on the fly. The following analytical parameters were obtained using the dual-
Au-SPE and putrescine as substrate: sensitivity 11.2±0.4 nA mg 1l, linear range 0.7–20.0 mg l-1 and LOD 
0.2 mg l-1. The biosensor has been used for ten consecutive calibration plots without a significant loss of 
performance for the first five, confirming a good reproducibility, taking into account that it had been obtained 
using a screen-printed disposable transducer. In order to reduce any kind of interference, the analysis of real 
samples was carried out by a differential method employing the dual SPE-based biosensor described above. 
The measurements were carried out on two white wines, two red wines and two blonde beers. The 
registered amperometric signals were referred to that of putrescine, thus obtaining the total amount of BAs, 
considering that the developed biosensor displayed the highest catalytic efficiency towards putrescine. 
Biosensor’s performances were validated using a modified reference method based on GC-MS analysis 
concluding that the  biosensors accurately measure the overall BAs content expressed as putrescine 
equivalent in both red and white wines, being less efficient in beer samples where  they measured only about 
50% of the BAs content. The fast response, minimal sample treatment, and high sensitivity of the apparatus 
indicate that it may conveniently be employed for production plants or in wineries in order to provide a 
reliable estimate of the content of biogenic amines, a parameter that is being increasingly demanded by food 
quality commissions [68].  
  
 Inflammatory bowel diseases  
 Crohn’s disease (CD) and ulcerative colitis (UC) are non-specific, non-infectious inflammatory bowel 
diseases (IBD) of the small and large intestine. They share several symptoms such as severe diarrhea, 
abdominal pain, vomiting, rectal bleeding, and high fever. However, while CD can affect any area of the 
gastrointestinal tract and is a deep destructive inflammation with a patchy and transmural tissue damage 
resulting in fibrosis and stenosis of the bowel, UC is confined to the rectum or to the distal part of the colon, 
and the ulceration does not go beyond the mucosa. Hereditary, immunologic and environmental factors are 
thought to be involved in the pathogenesis of IBD. According to accepted view, the disease develops in 
genetically predisposed hosts as a consequence of a disregulated immune response to enteric antigens 
resulting in continuous immune mediated inflammation and tissue damage. In CD, the responding T cells 
exhibit Th1, while in UC, Th2-phenotype lymphocytes are frequently found [69, 70]. In brief, Th1 lymphocytes 
secrete mainly IL-2, IFNγ and TNFα and are implicated in cell-mediated immunity, whereas Th2 cells secrete 
IL-4, IL-5 and IL-13 and are related to strong antibody responses [71, 72]. Recently, two more pro-
inflammatory interleukins, IL-17A and IL-17F, were found to be abundantly present in intestines of patients 
with UC and CD. These cytokines are products of newly disclosed and characterised Th17 lymphocytes. 
Helper Th17 cells produce all together six interleukins IL-17A-F, but beyond that, also IL-21, IL-22 and IL-9 
are produced. They link innate and adaptive  immunity mediated mucosal host responses to a number of 
gastrointestinal pathogens [73]. 
 During the last few years, the incidence of IBD, quite high in industrialised Western countries,  was 
more or less stabilized, but simultaneously, an increasing incidence rate has been observed in Finland, 
Eastern Europe and Asia [74]. Moreover, it has been reported that people who emigrate to Western 
countries have a higher risk for developing IBD, especially UC [75]. Noteworthy, UC and CD remain still 
incurable, despite considerable progress in the disclosure of underlying pathogenic mechanisms based on 
ongoing extensive clinical and experimental studies with various animal IBD models Table 1.   
Temporary remissions in IBD are followed by exacerbations of symptoms. Lately, the classic 
therapeutic approach, i.e. step-up therapy in relation to increased severity of IBD, is being confronted with a 
top-down strategy that involves early use of newly implemented immunomodulators and biological drugs 
Table 2. Opponents to these therapies indicate side effects of the latter, such as increased risk of infection, 
hepatitis, pancreatitis, demyelinating disorders and malignancy [76-79]. On the other hand, persistent 
chronic inflammation is known to be itself strongly associated with increased tumour incidence and 
progression. Patients with UC or CD have a 2-3 fold greater  risk of developing colorectal cancer than the 
general population [80]. The proponents of the top-down strategy stress that immune suppressants and 
biologics efficiently induce mucosal healing and maintain remission in CD patients, thus preventing 
irreversible damage of the bowel if used early, at onset of the disease [81, 82]. Thiopurines protect IBD 
patients against the development of advanced neoplasms [83].  However, in Caucasian patients these drugs 
increase a risk of non-melanoma skin cancer [84]. Arguments pro- and against top-down therapy in specific 
subgroups of IBD patients are reported in comprehensive reviews [82, 85, 86]. 
  Without doubt, new biologic therapies offer treatment possibilities to some patients otherwise 
without chances for cure with conventional drugs. However, up to 50% of IBD patients are refractory to anti-
cytokine compounds, or their positive response can cease with time. Patients treated with anti-TNF may 
experience severe side effects and extra-intestinal immune-mediated pathologies. Beyond that, these 
therapies are relatively expensive and have a narrow range of safety [81-83, 85, 86]. Therefore, the 
development of new strategies for combating the disease is a real challenge for IBD research. Anti-TNF 
therapy made it clear that apart the excessive production of proinflammatory cytokines, there is a defect in 
the function of regulatory principles in IBD.  
 In this respect, DAO may serve as a good approach. DAO is responsible for the catabolism of 
histamine and putrescine, both, and especially the latter, being intimately related to growth processes [87]. 
Histamine, widely distributed throughout the body, fulfills several important functions in the digestive tract: it 
stimulates secretion of gastric acid, other fluids and mucous, influences gut motility, stimulates growth and 
regeneration processes, increases collagen formation, participates in immediate allergic and inflammatory 
responses [88]. In healthy individuals, the enterochromaffin-like cells, mast cells and intramural nerves 
synthesize and supply histamine. In IBD individuals, mast cells hyperplasia is seen in inflamed mucosa and 
submucosa [89]. Besides the enhanced mastocytes, some other cells, including the infiltrating cells 
(macrophages, lymphocytes), contribute to produce or promote synthesis of histamine. Histidine 
decarboxylase can be induced by TNFα, IL-1, GM-CSF [90]. This induced or so-called “nascent” histamine, 
acts on specific targets and, upon signaling, undergoes immediate degradation; it is not stored. However, in 
IBD not only the number of mast cells is increased, but their releasability, too. Thus, higher amounts of 
secreted histamine and other mediators,  can be measured both in vivo [91, 92] or ex vivo, upon stimulation 
[93]. Histamine exerts a vast array of effects, interacting with four different G-protein coupled membrane 
receptors [94]. For example, via H1 receptors, histamine evokes smooth muscle or endothelial cell 
contractions [95]. The same receptors also participate  in increased vascular permeability and antibody 
production [96]. In turn, cytokine production, chemotaxis of mast cells and leukocytes (neutrophils, 
eosinophils), influx of calcium into these cells, which all define severity of inflammation, are mediated by H2 
and H4 receptors [97, 98]. Histamine influences the Th1 / Th2 lymphocyte balance, affecting selectively 
cytokine production [99]. As becomes evident in UC: a shift towards Th2, which it facilitates, results in more 
intensive inflammation and higher susceptibility to opportunistic infections and tumours. Histamine, through 
H2 receptors, also induces plateled activating factor (PAF) production, increases adhesion molecules and 
can augment MHC class II antigen expression, stimulating the influx of immune cells into the intestinal wall. 
As already pointed out, histamine may also play a major role in the growth of normal and malignant tissue as 
a regulator of proliferation and angiogenesis [87, 99].  
 Histamine action is terminated essentially by two catabolic enzymes mentioned above: DAO and 
histamine N-methyltransferase (HMT). DAO is abundantly present in the vertebrate intestine showing 
characteristic activity profiles along the digestive tract, and across the intestinal mucosa. A low, variable 
activity of DAO in the stomach is followed by a gradual increase of its activity through the jejunum reaching a 
peak in the ileum.  Its activity decreases towards the large intestine. Within the mucosa, the enzyme is 
present only in mature cells in the middle and in the tip of the villi. No DAO activity can be found in dividing 
crypt cells [1, 87]. Any disease involving intestinal mucosa damage seems associated with some loss of 
DAO activity.  Indeed, in Crohn's ileitis, DAO activity is reduced [100, 101] and the decrease ofactivity is 
correlated to the severity of mucosal damage. The disease recurrence is preceded by  a significant drop in 
DAO activity, making the tissue enzyme assay useful for  prediction of  the risk of recurrence or of 
anastomotic complications after resection [101]. DAO deficiency was claimed to be responsible for abnormal 
intestinal motility observed in CD patients. Small bowel circular muscle from CD patients  demonstrated in ex 
vivo assays a much enhanced contractile response to histamine, blocked by H1 receptor antagonists, but not 
modified by inhibitors of DAO [102]. In active UC, the decrease of DAO activity was much more pronounced 
than in CD; roughly 10% of normal DAO activity could be observed. However, during the remission phase, 
an over 5 fold increase above the regular activity was found and an antiproliferative rebound effect in these 
subjects was suggested [103]. Adaptive increase in the methylation pathway of histamine catabolism to 
compensate for the DAO deficit was reported [104]. Urinary methylhistamine output, significantly higher in 
acute  phases of IBD, showed a correlation with the intensity of inflammation [104]. CD patients have 
physiological tissue histamine  concentrations, while tissue histamine concentrations in UC patients are 
higher, suggesting a marked unbalance between histamine synthesis and its degradation [105].  
  Some evidence was published in the nineties, indicating that excess of histamine plays an important 
role in the symptomatology of the disease. Namely, ketotifen H1 antagonist, with some mast cell stabilizing 
potency, was reported to block eicosanoid accumulation by cultured colonic mucosa from UC patients [106]. 
Ebastine, another H1 blocker, was able to inhibit T cell migration and production of Th2 type cytokines by 
cultured lymphocytes and production of proinflammatory cytokines by macrophages isolated from healthy 
donors [107]. Interestingly, in a small group of children with moderate UC,  an improvement was noted with 
ketotifen treatment [108]. More recently, this problem was addressed in rat models of UC using histamine 
receptor antagonistic ligands. Histamine H1 (ketotifen), H2 (ranitidine) and dual H3/H4 (thioperamide) receptor 
ligands were administered immediately after UC induction and treatment was continued for 5 consecutive 
days [55]. In another study on rat UC model, two selective antagonists of H4 receptor (JNJ 10191584 and 
JNJ 7777120) were used [109]. Both studies have shown that interference with histamine signaling at the 
level of its receptors resulted in improvement of animal health; parallelly, the markers of inflammation as well 
as mucosal inflammation scores were lower. Benefits were most probably due to inhibition of histamine 
interaction with various components of the immunological system [96]. Recent work suggests that in the 
digestive system of patients with IBD, there is an up-regulation of H1 and H2 receptors [95]. 
 The second strategy was based on the idea that if the disease results from a lack of regulatory 
principle, therapy should deliver it. Therefore, DAO (a commercially available preparation from dog kidney, 
immobilized on Concanavalin A Sepharose) was administered via intraperitoneal route to rats immediately 
after intrarectal administration of 4% acetic acid for induction of intestinal injury and colitis. The 5 days 
therapy improved plasma ceruloplasmin and myeloperoxidase activity in the large bowel, colon injury, and 
inflammation scores. The colonic DAO activity in the treated rats was significantly higher, indicating enzyme 
binding by the tissue. 
 These results are very promising and suggest that appropriately prepared DAO formulations could 
be implemented in antiallergic and anti-inflammatory therapy. The remplacement of pancreatic enzymes has 
saved many lifes. DAO may prove equally successful in the future.  
 























Table 1. Some more common IBD animal models [110-114]. 




2,4,6-Trinitrobenzene sulfonic acid (TNBS) 
Oxazolone 
Dextran sulfate sodium 
Adoptive transfer models 
Heat shock protein (hsp) 60- 
specific CD8 T cells 
CD4+ CD45RBhi 
Gene knockout (KO) models 
 
Interleukin-2 KO/IL-2 receptor (R)α KO 
IL-10 KO 
T cell receptor (TCR) mutant 
Trefoil factor-deficiency 
TNF-3' untranslated region (UTR) KO 
Transgenic animal models 
 
Signal transducer and activating transcription-
4 (STAT-4) 
IL-7 transgenic 
HLA B27 transgenic 
Spontaneous Colitis C3H/HejBir mice 
SAMP1/Yit mice 
 
Table 2. Multiple treatment options for IBD [115-120] 
Synthetic drugs 
5- Aminosalicylates (mesalazines), 
glucocorticosteroids,  
Azathioprine, 6-mercaptopurine 
Methotrexate, cyclosporin A 
Biological therapeutic agents 
Proinflammatory cytokine inhibitors:  
anti-TNFα, anti-IL12/ 23, 
Anti-inflammatory cytokines: RHIL-10, RHIL-11 
Anti-integrins 
 
Patent review coverage on the treatment of allergy and inflammation 
Treatments based on inhibiting mast cell degranulation and histamine release 
 Inflammatory bowel diseases, such as UC and CD, present a chronic and relapsing intestinal 
inflammatory status that is principally caused by immune deregulation of the gut. Despite significant 
advances in therapeutic strategies (including corticosteroids, 5-aminosalicylates, immunomodulators), there 
is no efficacious method to treat IBD. As the inflammatory-mediated affections are complex and multi-
factorial, different strategies for prevention and treatment of inflammation have been proposed in various 
patent applications.  
New active molecules, such as novel pyrimidine derivatives, formulated as tablets, capsules, 
powders, solutions or suspensions, were reported for the treatment of IBD and of immunological diseases 
[121]. Other patent applications are based on some chemical compounds (bicyclic heteroaryl-substituted 
imidazoles, benzofuro- and benzothienopyrimidine, 2-aminopyrimidine) as modulators of histamine  receptor 
activity (H4R) exposed on eosinophils, basophils and mast cells, for treatment of different pathological 
conditions including allergy [122-124]. The release of inflammatory mediators is thus well controlled in the 
presence of these H4R modulators, blocking the leukocyte recruitment and hindering the inflammation 
process. Various suitable routes of delivery of these modulators are also proposed (e.g. oral, rectal, topical). 
For patients having a medical condition related to the histamine H1 receptor (H1R), such as allergy 
and inflammatory diseases, a RNAi-mediated inhibition of H1R was proposed [125]. The administration of 
RNAi silences the expression of the H1R, preventing the events occurring in histamine-mediated 
inflammatory responses. 
The inhibition of the binding of a histamine releasing factor to the immunoglobulin E (IgE) was 
reported to treat food allergy, allergic reactions or inflammatory reactions [126]. It is known that the histamine 
releasing factor contributes to the stimulation of the histamine release and to the production of IL-4 and IL-13 
cytokines from IgE-sensitized basophiles. Thioredoxin, a small dithiol protein, can also have a positive effect 
in the food allergy treatment, decreasing the allergenicity of  food allergens, as  reported in animal 
experiments [127]. 
Other bioactive compounds that can inhibit mast cell degranulation could also be of interest. Thus, 
various peptides were reported for the treatment of cutaneous inflammation (dermatitis, eczema,  psoriasis) 
and of different allergies (food sensitivity, anaphylaxis), being potentially useful to  treat also IBD by inhibiting  
mast cell degranulation, and, thus, reducing the release of histamine, cytokines and leukotrienes [128, 129]. 
In this context, these peptides could be successfully used to replace corticosteroids. 
A pharmaceutical composition containing a therapeutically effective amount of a naturally-derived 
isoorientin (extracts of aloe, rice plant, bamboo, etc), as an anti-histamine active ingredient, was reported by 
Woo et al. [130] for the prevention or treatment of different conditions associated to an excessive quantity of 
histamine. The important anti-histamine effect of isoorientin is based on the inhibition of histamine release 
from mast cells in a concentration-dependent way. Such compositions, administrated orally or parenterally, 
may be useful for the prevention and the treatment of allergy or inflammatory diseases,  where histamine 
plays a major role. 
A crude vegetal extract based on a hardy kiwifruit (Actinidia sp.) was reported to prevent and to treat 
allergy and non-allergic inflammatory  diseases (different forms of dermatitis, gastritis, enteritis, etc), 
principally, by inhibiting histamine release from mast  cells and by reducing the level of Th2 cytokines and IgE 
in serum [131, 132]. The vegetal extract can be formulated as  tablet,  capsule,  powder or  suspension 
[131]. Food supplements or pharmaceutical compositions based on plant extracts of Momordica sp. 
(Momordica charantia, Momordica dioica) [133], of Tiarella polyphylla [134] or of Allium vineale [135],  
formulated for systemic, oral or topical / transdermal administration, can also be used as pharmacologically 
active  compounds for the treatment of conditions or diseases associated with the release of histamine (food 
allergy, drug allergy, anaphylaxis). The extract of Tiarella polyphylla (containing tiarellic acid) was reported to 
exert suppressive effects on the production of IgE and of some cytokines (IL-4, IL-5, IL-13), and on leukocyte 
infiltration, being proposed as  food supplement or as  therapeutic agent to prevent or to treat the 
pathological conditions mentioned above [134]. 
 A herbal therapy, consisting of a mixture of Chinese herbs, such as FAHF-1/2 herbal formula, was 
reported by Xiu-Min and Sampson [136] for the treatment of food allergy, reducing mast cell degranulation 
and histamine release, lymphocyte proliferation and synthesis of IL-4, IL-5 and IL-13. This herbal therapy 
can be administered with a pharmaceutically adequate carrier, adjuvant or vehicle (orally, parenterally, 
intraperitoneally, topically, etc), and used in combination with other active agents, such as anti-histamines. 
Compared to standard immunosuppressive therapy, generally using corticosteroids, it seems that this herbal 
therapy is more selective for the allergic response. 
Other compositions (comprising luteolin from Perilla leaf or seed, Cinnamon, Kiwi, Hesperidin etc), 
which prevent or inhibit the release of histamine, prostaglandin D2 and/or leukotriene C4, and thus  reduce or 
stop allergic or inflammatory  responses, were also reported [137]. 
 
Other proposed therapies for inflammation 
 Novel bioactive polyamine analogs and their derivatives, used to inhibit the expression or activity of 
TNFα and/or different cytokines ( IL-2, IL-6, IL-8, IL-12, etc) that usually are expressed in inflammatory 
diseases,  have been reported [138]. These bioactive agents can be used in combination with other active 
anti-inflammatory agents. An anti-inflammatory therapeutic composition, principally based on γ-tocopherol 
and/or on esters of gamma-tocoferol, was reported to reduce inflammation in IBD by diminishing the 
expression of endothelial cell adhesion molecules in the vasculature of the bowel wall, additionally to the 
antioxidant use of γ-tocoferol [139]. 
 
Amine oxidases in treatment of allergy and other histamine–mediated conditions 
 Oxygen-free radicals are known as pro-inflammatory agents. Wu and McIntire [140]  postulated a 
new treatment for pathologies associated with oxidative damage, providing compositions comprising at least 
one recombinant peroxisomal polyamine oxidase (PAO) to treat inflammation or other pathological 
conditions: for exemple PAO as antioxidant in ischemia/reperfusion and as pro-oxidant in cancers (due to the 
released H2O2). Thus, the invention relates to intracellular polyamine dysregulation, as it was observed that 
some elevated levels of polyamines are associated with reduced PAO activity. Pharmaceutical compositions 
comprising  recombinant PAO may be administered either systemically or locally. 
 AOs were reported as useful biosensors for the detection of histamine in food and  beverages, as  
mono-enzymatic system (AO) or  bi-enzymatic system (AO  and peroxidase) [141]. Based on the same 
principle of histamine degradation by AOs, a similar approach to degrade histamine was introduced by 
Missbichler et al. [142]. This recent patent application reported pharmaceutical compositions containing a 
DAO of animal origin (DAO from pig kidney or recombinant DAO prepared in cell cultures) for the treatment 
and/or prevention of histamine-induced conditions [142]. The composition containing DAO can be formulated 
for epidermal, oral or sublingual administration. For the oral administration of DAO, gastric-resistant pellets, 
coated with Eudragit or Shellac, and gelatine or starch capsules were used. 
 
Proposed innovative treatment of allergy and inflammation and its relationship with the reported 
patent applications 
 A new concept for the treatment of different  conditions, such as allergy, CD and UC, based on the 
oral administration of a vegetal DAO (VDAO) associated to catalase, was recently  disclosed [143]. An oral 
bi-enzymatic therapy with VDAO and catalase was suggested to reduce the levels of intestinal histamine via 
degradation by DAO, with the production of H2O2, NH3 and imidazole acetaldehyde. As H2O2, a by-product of 
degradation, is toxic, having pro-oxidant effects on intestinal cells, catalase was proposed, as second 
therapeutic enzyme, to decompose H2O2. The association of catalase and DAO has two major beneficial 
effects: first, catalase will prevent the local intestinal oxidative stress by decomposing H2O2 produced by 
VDAO, and, secondly, by decomposing H2O2, catalase will generate oxygen, a substrate for DAO. This may 
contribute to the enhancement of histamine oxidation and to a shift of equilibrium of the DAO enzymatic 
reaction towards the reaction products. Since the availability of oxygen in the colon is limited,  oxygen 
produced by the histaminase reaction will  probably be beneficial for the allergy or IBD treatment,  by more 
efficient degradation of intestinal histamine [144]. 
 As  already shown by Aschenbach et al. [145], an Organic Cation Transporter (OCT), located at the 
level of intestinal  junctions, contributes to the transport of histamine from the intestinal lumen into  systemic 
circulation. The same OCT also facilitates the transport of histamine from circulation into the intestinal lumen 
(bio-elimination), with the risk of readsorption Fig. (2). Our new concept of treatment by oral administration of 
VDAO associated to catalase, will prevent the readsorption of histamine into the systemic circulation, will 
enhance the intestinal bio-elimination of histamine and will eliminate the toxicity of H2O2. Catalase will also 
protect DAO from H2O2 produced by DAO itself (in the presence of histamine) or by other inflammatory 
reactions. 
 The design of oral delivery systems protecting sensible therapeutic agents such as VDAO and 
catalase [143] against digestive  enzyme degradation, represents a major challenge. By targeting the 
intestinal sites, these therapeutic enzymes must remain active to exert their therapeutical action. In this 
context, VDAO and catalase were formulated as monolithic tablets based on carboxymethyl starch (able to 
protect the enzyme against gastric acidity) associated with chitosan in order to deliver these bioactive agents 
to the colon [143, 144]. Other pharmaceutical excipients (i.e. metacrylates, chitosan, carboxymethyl starch or 
their mixtures) can also be used. 
As already mentioned above, histamine is an important mediator in several pathological conditions. 
The majority of the patent applications  reported here are focused on different strategies to reduce or to 
inhibit the release of histamine by: a) modulation of histamine receptors, administering various synthetic 
molecules [121-124] or RNAi that silences the expression of histamine receptors [125], b) inhibition of the 
binding of a histamine releasing factor to  IgE [126], c) suppression of IgE production [134], d) decrease of 
the allergenicity of food allergens by reducing the allergenic proteins containing disulfide bonds to the 
sulfhydryl (SH) level [127], e) reducing or inhibition of mast cell degranulation, administering different active 
agents, such as peptides [128, 129], naturally-derived isoorientin [130], vegetal extracts of Actinidia sp. [131, 
132] or other vegetal extracts [136]. 
The proposed innovative therapies of Mondovi et al. [24] and Mateescu et al. [143] are  mainly 
focused on  histamine degradation rather than on the reduction or inhibition of histamine release, such as 
reported in the majority of histamine–related patent applications here described. The new proposed therapy 
will act directly on histamine, degrading it before it exerts its effects. Thus, by using the proposed oral bi-
enzymatic therapy, histamine - mediated affections could be reduced or even prevented. Other patent 
applications for the therapy of allergy and inflammation are focused on histamine degradation by 
administration of different AOs as bioactive agents [140, 142, 145-147]. 
The application of Mateescu et al. [143]  is related to the patent of Mondovi et al. [146]  that 
proposed for the first time the use of a VDAO, formulated as spray and for topical applications, in the 
treatment of histamine - mediated conditions.  However, this disclosure [143] differs essentially from the 
previous one [146], by proposing a novel oral bi-enzymatic treatment of histamine-mediated intestinal 
conditions: an oral administration of  VDAO associated to catalase. Other patent applications describe the 
use of AOs produced by recombinant DNA techniques to treat  intestinal immune or inflammatory disorders 
related to histamine [140, 147]. The use of a vegetal histaminase presents several advantages, such as: (i) 
higher enzymatic activity (30-50 times) than the animal enzyme, (ii) larger accessibility (extraction from 
different vegetal sources using a simple procedure), (iii) less expensive  regarding production of large 
quantities, (iv) better acceptability of a vegetal agent by regulatory organisations. 
 Oral administration of DAO  in pharmaceutical compositions or as food supplements, used to 
degrade histamine at intestinal level, was mentioned for the first time in the patent application of Missbichler 
et al. [142]. The use of a non-vegetal DAO was preferred in this application due to the possible presence of 
allergens in vegetal extracts containing DAO. 
It is known that low doses of H2O2 generated in situ can exert anti-inflammatory effects [148] 
whereas, high concentrations of H2O2 can produce nocive effects, affecting cell viability. The difference and 
the advantage of the Mateescu et al. [143] application resides in the possibility to eliminate in situ the 
produced H2O2 resulting from histamine degradation or from other inflammatory reactions, by associating 
catalase to VDAO. This novel bi-enzymatic therapy proposes, first, to degrade histamine from the gut in the 
presence of VDAO (preventing its return into circulation), and, secondly, to decompose H2O2, the by-product 
of VDAO, by catalase. Furthermore, as reported for other copper oxidases [149-151], VDAO presents 
antioxidant properties, that complete its histaminase action. The antioxidant capacity of VDAO, counteracting 
the free radical species released at intestinal level, would be beneficial in the treatment of histamine-
mediated conditions. This novel approach of an oral bi-enzymatic formulation  of VDAO and catalase will be 
of high utility and will also open a new concept of  biopharmaceutically assisted clearance for various harmful 
biomolecules, particularly in systems where the toxicants (i.e. histamine or H2O2 by-product) are substrates 
for orally administered enzymes (i.e. VDAO and  catalase). 
 
CURRENT & FUTURE DEVELOPMENTS 
The majority of the patent applications reported here are focused on various strategies to reduce or to inhibit 
the re- lease of histamine (i.e., modulation of histamine receptors, suppression of IgE production, inhibition of 
mast cell de- granulation, etc.). Different from these strategies, the innovative therapies discussed in this 
review are mainly focused on histamine degradation rather than on the reduction or inhibition of histamine 
release. Thus, a natural enzymatic therapy of histamine-mediated diseases consisting of the administra- tion 
of a plant AO may open the way to alternative non-toxic and innovative therapeutic approaches for the 
control of dif- ferent histamine-mediated pathological conditions, such as allergy, anaphylaxis, intestinal 
ischemia, IBD. The plant AO will naturally decrease the level of harmful histamine, known to participate in 
the pathogenesis of the affections mentioned above. As the H2O2 by-product of AO is a prooxidant agent 
with some undesirable oxidative damaging effects, a bi-enzymatic treatment consisting of the association of 
the plant AO (DAO) with catalase, an enzyme de-composing H2O2, was proposed [138, 139]. In addition to 
its histaminase action, the vegetal DAO will probably exert antioxidative effects, such as previously 
described for other copper oxidases (i.e., ceruloplasmin, bovine serum amine oxidase). Since the oxidative 
stress is involved in different histamine-related pathogenesis, in the future, it will be of interest to have a 
better understanding of the additional anti- oxidant properties of plant AOs. 
Different approaches of plant AOs forms of administra- tion are presented here (i.e., systemic, oral 
administration). Various strategies for targeting plant AOs release selectively to different sites have to be 
developed in the future. A challenging way will be the oral route to administer AO in order to control the 
histamine-mediated pathological conditions at intestinal level. These novel therapies for the histamine- 
related pathologies have to be further proven in experimental models of the disease in animals and also in 
humans. 
An important aspect is the acceptability of natural vegetal therapeutic protein for oral administration. The 
AOs also present a potential role in tumor therapy. When formulated with excipients as pharmaceutical forms 
for colon delivery, they can be used for intestinal cancer therapy in association or not with other antitumor 
chemotherapeutic drugs. 
In conclusion, the recent advances in understanding the beneficial actions of plant AOs in histamine-
mediated affec- tions make plant AO an interesting biopharmaceutical molecule. Different from the current 
proposed therapies of the histamine-mediated conditions mentioned above, the admini- stration of a plant 
AO could represent a safe and non-toxic alternative that can completely replace or act complementary. 
with other existing treatments. Thus, natural treatments will ensure patient compliance, better patient health 
and im- proved quality of life. 
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Fig.  (2). Model depicting intestinal elimination of histamine 
    DAO: Diamine Oxidase; OTC: Organic Cation Receptor. 
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